Next Article in Journal
Diversity and Adaptations of Escherichia coli Strains: Exploring the Intestinal Community in Crohn’s Disease Patients and Healthy Individuals
Next Article in Special Issue
Editorial for Special Issue: Microbial and Autoimmune Disease
Previous Article in Journal
Nasal Methicillin-Resistant Staphylococcus aureus Colonization in Patients with Type 1 Diabetes in Taiwan
Previous Article in Special Issue
May Bacterial Infections Trigger Bullous Pemphigoid? Case Report and Review of Literature
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 9
Issue 6
10.3390/microorganisms9061298
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Oral Lactobacillus Species in Systemic Sclerosis

by
Daniela Melchiorre
1,*,†,
Maria Teresa Ceccherini
2,†,
Eloisa Romano
1,
Laura Cometi
1,
Khadija El-Aoufy
1,
Silvia Bellando-Randone
1,
Angela Roccotelli
2,
Cosimo Bruni
1,
Alberto Moggi-Pignone
1,
Davide Carboni
1,
Serena Guiducci
1,
Gemma Lepri
1,
Lorenzo Tofani
1,
Giacomo Pietramellara
2 and
Marco Matucci-Cerinic
1
1
Department of Experimental and Clinical Medicine, Department of Geriatric Medicine, Division of Rheumatology, University of Firenze, 50124 Firenze, Italy
2
Department of Agriculture, Food, Environment and Forestry (DAGRI)-University ofFirenze, 50144 Firenze, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Microorganisms 2021, 9(6), 1298; https://doi.org/10.3390/microorganisms9061298
Submission received: 15 April 2021 / Revised: 7 June 2021 / Accepted: 11 June 2021 / Published: 15 June 2021
(This article belongs to the Special Issue Microbial and Autoimmune Disease)
Browse Figure
Review Reports Versions Notes

Abstract

:
In systemic sclerosis (SSc), the gastrointestinal tract (GIT) plays a central role in the patient’s quality of life. The microbiome populates the GIT, where a relationship between the Lactobacillus and gastrointestinal motility has been suggested. In this study, the analysis of oral Lactobacillus species in SSc patients and healthy subjects using culture-independent molecular techniques, together with a review of the literature on microbiota and lactobacilli in SSc, has been carried out. Twenty-nine SSc female patients (mean age 62) and twenty-three female healthy subjects (HS, mean age 57.6) were enrolled and underwent tongue and gum swab sampling. Quantitative PCR was conducted in triplicate using Lactobacillus specific primers rpoB1, rpoB1o and rpoB2 for the RNA-polymerase β subunit gene. Our data show significantly (p = 0.0211) lower LactobacillusspprpoB sequences on the tongue of patients with SSc compared to HS. The mean value of the amount of Lactobacillus ssprpoB gene on the gumsofSSc patients was minor compared to HS. A significant difference between tongue and gums (p = 0.0421) was found in HS but not in SSc patients. In conclusion, our results show a lower presence of Lactobacillus in the oral cavity of SSc patients. This strengthens the hypothesis that Lactobacillus may have both a protective and therapeutic role in SSc patients.

1. Introduction

The pathogenesis of systemic autoimmune diseases, including systemic sclerosis (SSc), is complex and characterized by auto-reactive immune responses that cause immune-mediated organ damage [1,2,3,4]. Indeed, despite the fact that pathogenetic aspects have not yet been completely elucidated, environmental factors (lifestyle, diet, drugs and infections) acting on people with permissive genetic assets have been proposed [2].
Among the different environmental factors, one that stands out is the microbiota, which is the whole composition of microorganisms, mainly bacteria, but even fungi and viruses, that densely populate the human body [5,6]. They represent about 90% of the cells associated with any human being [6], and their genome and ecosystem are called the microbiome. It is assumed that a minimum of 1000 species are involved [2], with extreme variability between individuals and also within each individual, depending on the body site sampled and the time of sampling [7]. The microbiome occupies different habitats, such as skin and mucosal surfaces. The great majority is found in the gastrointestinal tract (GIT) and the predominant phyla are Bacteroidetes and Firmicutes [6,8]. The GIT microbiota plays a pivotal role in the immune system’s development, homeostasis, and function. Emerging evidence suggests that GIT dysbiosis (changes in the composition of the microbiota, such as the loss of beneficial microorganisms, excessive growth of potentially harmful organisms, loss of overall microbial diversity) leads to a loss of tolerance and the subsequent development of a rheumatic disease, including rheumatoid arthritis (RA), spondyloarthritis, Sjögren’ssyndrome and SSc [2,5,8,9].
In SSc, GIT involvement is one of the key features with a great impact on the patient’s quality of life [9]. Symptoms of lower GIT involvement, such as constipation, abdominal pain, diarrhea, fecal incontinence, malabsorption, and weight loss, are among the more disruptive physical problems and have a great impact on the SSc patient. The alterations in peristalsis may favor dysbiosis and systemic bacterial translocation, both of which have the potential to alter systemic immune responses, and the vasculopathy may alter mucosal barrier function, integrity, and gut homeostasis [1]. Furthermore, small intestinal bacterial overgrowth is a well described complication associated with GI dysmotility, discomfort and malnutrition [10]. However, the etiology of SSc-related lower GI dysfunction is largely unknown, and no effective treatment options are currently available.
Observational studies have demonstrated that Lactobacillus, frequently associated with Bifidobacterium, was recognized to be increased at gut level in SSc patients, two commensal genera typically less present in chronic inflammatory status [8,11,12,13,14]. In particular, Lactobacillus was found to be greater in patients with limited than in diffuse cutaneous sclerosis [12]. An increase in colonic Lactobacillus has also been observed in different cohorts, and a link between members of the Lactobacillus genus and gastrointestinal motility has been suggested.
The Lactobacillus genus is a relevant representative of the Firmicutes phylum. It is a very complex genus with several species, and it was recently reorganized from a taxonomic point of view by adding further species [15]. It is a normal constituent of the microbiota, even though only a minority of species are autochthonous to the human GIT, the large majority being considered allochthonous [16], and it has generally been associated with beneficial activity [14]; in fact, there are a lot ofstudies on its use as a probiotic [17] and even in health it seems to be associated with an anti-inflammatory activity [18], whereas only rarely it has been described to behave as an opportunistic microorganism [19]. Despite the fact that Lactobacillus has been successfully used as a probiotic/anti-inflammatory agent in experimental models of systemic immune-mediated inflammatory diseases since the end of the last century [20,21,22,23,24,25,26] and its presence has been associated with anti-inflammatory activity [27], in the saliva of primary Sjögren’ssyndrome [28] and in the gut of RA [29,30] and SSc, it has been repeatedly found at an increased level [11,12,13,14] and associated with GIT pathologic involvement [12], thus casting some doubts on the actual association with anti-inflammatory activity (Table 1). Conversely, nothing is known, to the best of our knowledge, on the role and the levels of oral Lactobacillus in SSc patients. It is well known that the oral microbiome deeply influences the gut microbiome, so that they are strictly interwoven. Moreover, the importance of the oral microbiome as a cause of both oral and systemic diseases was recently evaluated. This is due to the transformation of commensal bacteria into opportunistic bacteria inside the oral cavity, which are able to determine the onset of pathologic conditions either limited to the oral cavity, including caries, gingivitis, periodontitis, and tonsillitis, or systemic [31,32]. Clinical studies have associated periodontopathic bacteria with some systemic disorders, such as RA, which seem to have similar physio-pathological mechanisms. In fact, periodontal bacteria are reported to induce the production of neutrophil, monocyte and T and B-mediatedimmune responses and the release of proteinases, cytokines and prostaglandins, causing bone osteoclastactivity and bone erosion, similar to the pathophysiology of RA [33].
The aim of this study was to apply the molecular analysis of quantitative polymerase chain reaction (PCR) on oral Lactobacillus spp. in SSc patients and sex- and age-matched healthy controls.

2. Materials and Methods

Consecutive SSc outpatients of the Rheumatology Unit of AOU Careggi, Firenze, Italy, were enrolled in our study. Patients were classified according to ACR 2013 criteria and for each patient clinical and anamnestic data were collected (type of disease and type of organ involvement, antibody profile, therapies performed, PRO questionnaire (HAQ, VAS, UCLA-GIT)). Inclusion criteria were age >18 years old, diagnosis of SSc, absence of active periodontal disease or dental caries, absence of other systemic diseases, and a regular dietary regimen. The exclusion criteria were the recent use (1 month) of antibiotic/antifungal therapy, the use of probiotics, the presence of periodontal disease or dental caries and a particular dietary regimen. Healthy subjects (HS), who did not present active periodontal disease or dental caries and did not follow a particular dietary regimen, were also analyzed.
Patients and HS signed an informed consent form to participate in the study, all procedures were carried out in accordance with the Helsinki Declaration of 1964 and the study was approved by the local ethical committee (15013/CAM_BIO).
The patients and HS included in the study were subjected to a sampling of tongue and gum swabs (sterile swabs with cap in polyethylene, inserted in tube in polypropylene with plastic shaft in dry transport media. Biosigma spa, Italy). The nurse (K.E.-A.) performed a gum swab in patients and HS by repeated rubbings on all surfaces of gingival tissue (internal and external surfaces of the gums, in the upper and lower part of the mouth). The tongue swab was performed by repeated rubbings of the swab over the entire lingual surface (on the lateral, upper and lower parts of the tongue). All samples were delivered to the laboratory and stored at −80 °C before DNA extraction.

2.1. DNA Extraction and Quantification of Lactobacillus

Total DNA was extracted from the swabs sampled by the nurse from SSc patients and HS by QIAampDNAStool Mini Kit instructions (Qiagen, S.r.l. Italy) and quantified with a Qubit® 2.0 fluorometer (Invitrogen, Thermofisher Scientific, Milano, Italy); the qualityof DNA was checked on 1.5% agarose gel. Quantitative PCR (qPCR) was conducted using the specific primers rpoB1, rpoB1o and rpoB2 for the RNA-polymerase β subunit encoding gene, a valuable alternative as present in a single copy per genome, whichgenerate amplicons of 250-bp, on 40 ng DNA for all the samples; negative control contained only ddH2O. Reactions were performed in a CFX Connect 96 apparatus (BioRad, Hercules, CA, USA) and the results were analyzed by the manufacturer’s software. Amplification was carried out in a 25 μL final volume containing: 7.5 μM of each primer, 1X iTaq™ Universal SYBR®GreenSupermix, sterile ddH2O to reach the appropriate volume. Amplification was performed in 96-well microtiter plates (BioRad). The program cycle was: 95 °C 3 min followed by 35 cycles of 95 °C 1 min, 45 °C 1 min and 72 °C 1 min. After that, a melting curve program was run for which measurements were made at 0.5 °C temperature increments every 10 s within a range of 60–100 °C. A rpoB amplified and purified fragment (froma mix of LABs of a commercial probiotic formulation—Lactoflorene® Plus, Montefarmaco OTC, Milano, Italy) was used as standard [34]. The standard curve was developed by plotting the logarithm of known concentrations (tenfold dilution series in triplicate from 1 × 10−1 to 1 × 10−6 in 25 μL reaction) of the rpoB fragment against the threshold cycle (Ct) values. The qPCR standard curve had an R2 of 0.99–0.97 and an efficiency >85%. Three replicates were carried out for each sample. rpoBsequences were expressed in ng DNA ng−1 of template DNA.

2.2. Statistical Analysis

To evaluate the difference in Lactobacillus qPCR in gum and tongue between groups, a GEE (generalize estimating equation) linear regression model was used. Student’s t test for continuous variables was also used.

3. Results

3.1. Patients and Healthy Subjects

Twenty-nine consecutive SSc female outpatients (mean age ± standard deviation (SD) 62 ± 12.43; range 43–80 years) of the Rheumatology Unit of AOU Careggi, Firenze, Italy, were enrolled. Out of 29 patients, 13 showed limited cutaneous systemic sclerosis (lcSSc), 15 diffuse cutaneous systemic sclerosis (dcSSc), 1 overlap syndrome. There were seven current and nine former smokers. Twenty-three female and age-matched healthy subjects (HS, mean age ± SD 57.6 ± 8.46; range 44–72 years), seven of whom were current and fivewere former smokers, were also analyzed. There was no significant difference between patients and HS for smoking habits (Table 2).
LcSSc group: all patients had a mean disease duration of 12 years and showed anti-nuclear antibody (ANA) and anti-centromere antibody (ACA) positivity (one patient was also anti-RNA polymerase-3 positive). Six patients were on chemical Disease Modifying Anti-Rheumatic Drugs (cDMARD) therapy (two mycophenolate mofetil, four hydroxychloroquine), three patients were on i.v.prostanoid (iloprost), and one patient had previously been treated with cyclophosphamide. Smoking was reported in seven patients (four current smokers and three former smokers).
DcSSc group: all patients had a mean disease duration of 14 years and showed ANA and anti-Scl70 positivity (one patient was also anti-RNA polymerase-3 positive). Ten patients were receiving cDMARD (two corticosteroids, two azathioprine, one methotrexate, five hydroxychloroquine) and three of them were taking IVIG, 10 patients were on i.v.prostanoid (seveniloprost, three alprostadil), and two patients had been previously treated with cyclophosphamide. Three were current smokers and six were former smokers.
One patient presented with overlap syndrome characterized by ANA, anti-Scl70, anti-SSA, and anti-SSB positivity with a long-lasting disease (22 years) and was on hydroxychloroquine and golimumab (Table 2).

3.2. Lactobacillus rpoB Quantification in Tongue Samples

The mean value of the amount of Lactobacillus spp. rpoB gene in tongue samples of SSc patients was 4.14 × 10−6 (±88 × 10−6) ng ng−1 DNA.The mean value of the amount of Lactobacillus spp. rpoB gene of HS was 7.09 × 10−6 (±7.21 × 10−6) ng ng−1 DNA. A significant difference was detected between the two groups (p = 0.0211).

3.3. Lactobacillus rpoB Quantification in Gum Samples

The mean value of the amount of Lactobacillus spp. rpoB gene in gum samples was 3.55 × 10−6 (±3.72 × 10−6) ng ng−1DNA in SSc patients. The mean value of the amount of Lactobacillus spp. rpoBin HS was 3.72 × 10−6 (±3.93 × 10−6) ng ng−1 DNA. No significant differences were detected between the two groups.
The rpoB sequence number per ng of template DNA quantified by qPCR was significantly different between tongue and gum (p = 0.0421) in HS, whereas no significant differences were detected in SSc patients (Figure 1).

4. Discussion

The possibility that the microbiome may influence the onset and the severity of autoimmune diseases has become a field of active studies in the last few years. Teodorescu et al. have reported that chronic periodontitis can be more frequent in adults. This periodontal destruction could be directly correlated with biofilm and calculus deposits, the progression rate is slow to moderate and the patient can also present local and general risk factors as systemic diseases [35]. The molecular methods more precisely reflect the true microbial local situation, considering that their sensitivity compared to the traditional cultural methods is much higher [34,36]. However, in spite of all these technical developments and the net increase in the relative studies, only a few certainties have been reached up to now. The role of Lactobacillus species is controversial (Table 1). This is also true for other rheumatic diseases in which an increase in the quantity of Lactobacillus has been found [17,18,37,38,39,40,41], but more recently the opposite has been observed [12].
Conversely, Lactobacillus has been found consistently increased in the gut microbiota of patients with SSc in studies from the US, Italy and Norway [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42]. Lactobacillus and Bifidobacterium, two commensal genera, are typically less present in the chronic inflammatory status, and Lactobacilla were found to be greater in patients with limited cutaneous sclerosis than in diffuse cutaneous sclerosis [8]. These aspects cast some doubts on the protective role of Lactobacillus ssp. in SSc, as it appears to be so in RA. However, nothing is known, to the best of our knowledge, on the presence of oral Lactobacillus in patients with SSc, in spite of the relevance of this information, considering its possible local anti-inflammatory activity, a body district which is profoundly involved in SSc patients, and the possibility of modulating the Lactobacillus presence through dietary and/or drug interventions. Smoking does not seem to influence the oral Lactobacillus, considering that Lactobacillus is only enriched in currentsmokers [43], who were not different in SSc patients compared with HS. Our data show a significant difference in Lactobacillus spp. rpoB gene levels between HS and SSc patients. Lactobacillus spp. rpoB gene levels are much lower on the tongues of SSc patients, suggesting the involvement of oral Lactobacillus in the SSc local modulation. Although microbial abundance in gut microbiota is generally considered dependent on the levels observed in the oral microbiota, this does not seem to be the case for Lactobacillus in SSc patients, perhaps for a number of reasons largely unknown, but which may allow us to hypothesize that the oral cavity of SSc patients may be quite an inhospitable environment for Lactobacillus, which may find a more welcoming survival niche at the colonic mucosa. Lactobacillus species offer exciting research opportunities, both in terms of biomedical applications and in acquiring fundamental knowledge about the functionality of gut microbes. It is also important to underline that lactic bacteria, due to their pro-bioactive cellular substances, are considered probiotic agents with an important role in the human microbiome and are not involved in oral diseases [34,44,45,46,47,48,49,50,51,52,53,54,55,56]. Their use could improve the quality of life of rheumatic patients, and in particular the possible therapeutic role of Lactobacillus in patients suffering from SSc or other rheumatic diseases is suggestive. The bacteria residing in the mammalian gut and their hosts are likely to have coevolved over a long-conjoined history and, by doing so, have developed an intimate and complex symbiotic relationship. The mechanisms underlying these interactions are likely to be specific for a particular microbe and its host and are probably influenced by other partners of the gut microbiota. Therefore, investigations of the host/microbe interplaying gut ecosystems should be conducted within an ecological context. It is reasonable to consider that native strains are better probiotic strains for some applications [57,58]. It has been clearly shown that gut microbes benefit their host in many aspects. In fact, gut bacteria can enhance host immune functions and the mucosal barrier, and they provide protection against incoming microbes [11,59,60,61,62,63,64,65,66].
Our investigation aimed to explore the potential protective role of oral Lactobacillus in SSc patients, considering that reduced microbial richness found in SSc gut was associated with a worse prognosis, such as a diffuse skin subset, poor nutritional status or a longer duration of the disease [14].
Our data show that the number of Lactobacillus on the tongue of patients is about half that of HS. Moreover, the statistical analysis performed showed a significant difference between the Lactobacillus present on the gums and those present on the tongue of HS in contrast to what was obtained in SSc patients, in whom no significant difference was found.
It is noteworthy that this is the first time, to the best of our knowledge, that a statistically significant reduction in Lactobacillus in the oral cavity of SSc patients has been demonstrated. This allows us to hypothesize the possible protective role of Lactobacillus, in line with its well-known association with anti-inflammatory activity [21], and consequently possible intervention strategies, based on Lactobacillus-containing probiotic administration, in an autoimmune disease in which the available therapeutic tools are currently very poor.

Author Contributions

D.M. and M.T.C. designed the study. E.R., L.C., D.C., K.E.-A. and G.L. collected and stored the samples. S.B.-R., C.B., A.M.-P. and S.G. interviewed the patients. M.T.C. and G.P. analyzed and interpreted the data. L.T. carried out the statistical analysis. A.R. extracted DNA from the swabs sampled. M.T.C. wrote the manuscript. M.M.-C. interpreted data and critically revised the manuscript. All the authors substantively revised the work; approved the submitted version (and the version substantially edited by journal staff that involves the author’s contribution to the study); and agreed to be personally accountable for the author’s own contributions and for ensuring that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and documented in the literature. All authors have read andagreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of Careggi Hospital (protocol code 15013/CAM_BIO/08-10-2019).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Konig, M.F. The microbiome in autoimmune rheumatic disease. Best Pract. Res. Clin. Rheumatol. 2020, 34, 101473. [Google Scholar] [CrossRef] [PubMed]
  2. De Luca, F.; Shoenfeld, Y. The microbiome in autoimmune diseases. Clin. Exp. Immunol. 2019, 195, 74–85. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Varga, J.; Trojanowska, M.; Kuwana, M. Pathogenesis of systemic sclerosis: Recent insights of molecular and cellular mechanisms and therapeutic opportunities. J. Scleroderma Relat. Disord. 2017, 2, 137–152. [Google Scholar] [CrossRef]
  4. SaveriaFioretto, B.; Rosa, I.; Romano, E.; Wang, Y.; Guiducci, S.; Zhang, G.; Manetti, M.; Matucci-Cerinic, M. The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: A comprehensive overview. Ther. Adv. Musculoskelet. Dis. 2020, 12, 1–24. [Google Scholar] [CrossRef]
  5. Nikitakis, N.G.; Papaioannou, W.; Sakkas, L.I.; Kousvelari, E. The autoimmunity-oral microbiome connection. Oral Dis. 2017, 23, 828–839. [Google Scholar] [CrossRef] [PubMed]
  6. Scofield, R.H. Rheumatic disease and the microbiome. Int. J. Rheum. Dis. 2014, 17, 489–492. [Google Scholar] [CrossRef] [Green Version]
  7. Yeoh, N.; Burton, J.P.; Suppiah, P.; Reid, G.; Stebbings, S. The role of the microbiome in rheumatic diseases. Curr. Rheumatol. Rep. 2013, 15, 314. [Google Scholar] [CrossRef]
  8. Bellocchi, C.; Volkmann, E.R. Update on the Gastrointestinal Microbiome in Systemic Sclerosis. Curr. Rheumatol. Rep. 2018, 20, 49. [Google Scholar] [CrossRef]
  9. Morrisroe, K.; Murray, B.; Tracy, F.; Mandana, N. Small intestinal bacterial overgrowth in systemic sclerosis. J. Scleroderma Relat. Disord. 2019, 5, 33–39. [Google Scholar] [CrossRef]
  10. Andréasson, K.; Alrawi, Z.; Persson, A.; Jönsson, G.; Marsal, J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res.Ther. 2016, 18, 278. [Google Scholar] [CrossRef] [Green Version]
  11. Volkmann, E.R.; Chang, Y.L.; Barroso, N.; Furst, D.E.; Clements, P.J.; Gorn, A.H.; Roth, B.E.; Conklin, J.L.; Getzug, T.; Borneman, J.; et al. Systemic sclerosis is associated with a unique colonic microbial consortium. Arthritis Rheumatol. 2016, 68, 1483–1492. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Volkmann, E.R.; Hoffmann-Vold, A.M.; Chang, Y.L.; Jacobs, J.P.; Tillisch, K.; Mayer, E.A.; Clements, P.J.; Hov, J.R.; Kummen, M.; Midtvedt, Ø.; et al. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol. 2017, 4, e000134. [Google Scholar] [CrossRef]
  13. Patrone, V.; Puglisi, E.; Cardinali, M.; Schnitzler, T.S.; Svegliati, S.; Festa, A.; Gabrielli, A.; Morelli, L. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci. Rep. 2017, 7, 14874. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Natalello, G.; Bosello, S.L.; Paroni Sterbini, F.; Posteraro, B.; De Lorenzis, E.; Canestrari, G.B.; Gigante, L.; Verardi, L.; Ferraccioli, G.; Sanguinetti, M.; et al. Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status. Clin. Exp. Rheumatol. 2020, 38 (Suppl. 125), S73–S84. [Google Scholar]
  15. Zheng, J.; Wittouck, S.; Salvetti, E.; Franz, C.M.A.P.; Harris, H.M.B.; Mattarelli, P.; O’Toole, P.W.; Pot, B.; Vandamme, P.; Walter, J.; et al. A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int. J. Syst. Evol. Microbiol. 2020, 70, 2782–2858. [Google Scholar] [CrossRef]
  16. Zhong, D.; Wu, C.; Zeng, X.; Wang, Q. The role of gut microbiota in the pathogenesis of rheumatic diseases. Clin. Rheumatol. 2018, 37, 25–34. [Google Scholar] [CrossRef]
  17. Linares, D.M.; Gómez, C.; Renes, E.; Fresno, J.M.; Tornadijo, M.E.; Ross, R.P.; Stanton, C. Lactic Acid Bacteria and Bifidobacteria with Potential to Design Natural Biofunctional Health-Promoting Dairy Foods. Front. Microbiol. 2017, 8, 846. [Google Scholar] [CrossRef]
  18. Brusca, S.B.; Abramson, S.B.; Scher, J.U. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr. Opin. Rheumatol. 2014, 26, 101–107. [Google Scholar] [CrossRef] [Green Version]
  19. Goldstein, E.J.; Tyrrell, K.L.; Citron, D.M. Lactobacillus species: Taxonomic complexity and controversial susceptibilities. Clin. Infect. Dis. 2015, 60 (Suppl. 2), S98–S107. [Google Scholar] [CrossRef] [Green Version]
  20. Matsuzaki, T.; Nagata, Y.; Kado, S.; Uchida, K.; Kato, I.; Hashimoto, S.; Yokokura, T. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 1997, 105, 643–649. [Google Scholar] [CrossRef]
  21. Kano, H.; Kaneko, T.; Kaminogawa, S. Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collagen-induced arthritis in mice. J. Food Prot. 2002, 65, 153–160. [Google Scholar] [CrossRef] [PubMed]
  22. Baharav, E.; Mor, F.; Halpern, M.; Weinberger, A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J. Nutr. 2004, 134, 1964–1969. [Google Scholar] [CrossRef] [PubMed]
  23. So, J.S.; Lee, C.G.; Kwon, H.K.; Yi, H.J.; Chae, C.S.; Park, J.A.; Hwang, K.C.; Im, S.H. Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol. Immunol. 2008, 46, 172–180. [Google Scholar] [CrossRef] [PubMed]
  24. Lavasani, S.; Dzhambazov, B.; Nouri, M.; Fåk, F.; Buske, S.; Molin, G.; Thorlacius, H.; Alenfall, J.; Jeppsson, B.; Weström, B. A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. PLoS ONE 2010, 5, e9009. [Google Scholar] [CrossRef]
  25. Kwon, H.K.; Kim, G.C.; Kim, Y.; Hwang, W.; Jash, A.; Sahoo, A.; Kim, J.-E.; Nam, J.H.; Im, S.-H. Amelioration of experimental autoimmune encephalomyelitis by probioticmixture is mediated by a shift in T helper cell immune response. Clin. Immunol. 2013, 146, 217–227. [Google Scholar] [CrossRef]
  26. Johnson, B.M.; Gaudreau, M.C.; Al-Gadban, M.M.; Gudi, R.; Vasu, C. Impact of dietary deviation on disease progression and gut microbiome composition in lupus-prone SNF1 mice. Clin. Exp. Immunol. 2015, 181, 323–337. [Google Scholar] [CrossRef] [Green Version]
  27. Walter, J. Ecological role of lactobacilli in the gastrointestinal tract: Implications for fundamental and biomedical research. Appl. Environ. Microbiol. 2008, 74, 4985–4996. [Google Scholar] [CrossRef] [Green Version]
  28. Sharma, D.; Sandhya, P.; Vellarikkal, S.K.; Surin, A.K.; Jayarajan, R.; Verma, A.; Kumar, A.; Ravi, R.; Danda, D.; Sivasubbu, S.; et al. Saliva microbiome in primary Sjögren’s syndrome reveals distinct set of disease-associated microbes. Oral Dis. 2020, 26, 295–301. [Google Scholar] [CrossRef]
  29. Liu, X.; Zou, Q.; Zeng, B.; Fang, Y.; Wei, H. Analysis of fecal Lactobacillus community structure in patients with early rheumatoid arthritis. Curr. Microbiol. 2013, 67, 170–176. [Google Scholar] [CrossRef]
  30. Zhang, X.; Zhang, D.; Jia, H.; Feng, Q.; Wang, D.; Liang, D.; Wu, X.; Li, J.; Tang, L.; Li, Y.; et al. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nat. Med. 2015, 21, 895–905. [Google Scholar] [CrossRef]
  31. Walker, M.Y.; Pratap, S.; Southerland, J.H.; Farmer-Dixon, C.M.; Lakshmyya, K.; Gangula, P.R. Role of Oral and Gut Microbiome in Nitric Oxide-Mediated ColonMotility. Nitric Oxide 2018, 73, 81–88. [Google Scholar] [CrossRef]
  32. Martu, I.; Goriuc, A.; Martu, M.A.; Vata, I.; Baciu, R.; Mocanu, R.; Surdu, A.E.; Popa, C.; Luchian, I. Identification of bacteria involved in periodontal disease using molecular biology techniques. Rev. Chim. 2017, 68, 2407–2412. [Google Scholar] [CrossRef]
  33. Martu, M.A.; Solomon, S.M.; Sufaru, I.G.; Jelihovschi, I.; Martu, S.; Rezus, E.; Surdu, A.E.; Onea, R.M.; Grecu, G.P.; Foia, L. Study on the prevalence of periodontopathogenic bacteria in serum and subgingival bacterial plaque in patients with rheumatoid arthritis. Rev. Chim. 2017, 68, 1946–1949. [Google Scholar] [CrossRef]
  34. Luisi, M.L.E.; Lucarini, L.; Biffi, B.; Rafanelli, E.; Pietramellara, G.; Durante, M.C.; Vidali, S.; Provensi, G.; Madiai, S.; Gheri, C.F.; et al. Effect of Mediterranean Diet Enriched in High 482 Quality Extra Virgin Olive Oil on Oxidative Stress, Inflammation and Gut Microbiota in Obese and Normal Weight Adult Subjects. Front.Pharmacol. 2019, 10, 1366. [Google Scholar] [CrossRef] [Green Version]
  35. Teodorescu, A.C.; Teslaru, S.; Solomon, S.M.; Zetu, L.; Luchian, I.; Sioustis, I.-A.; Martu, M.A.; Valiliu, B.; Martu, S. Assessment of Bacterial Associations Involved in Periodontal Disease Using Crevicular Fluid. Rev. Chim. 2019, 70, 2145–2149. [Google Scholar] [CrossRef]
  36. Solomon, S.M.; Bataiosu, M.; Popescu, D.M.; Rauten, A.M.; Gheorghe, D.N.; Petrescu, R.A.; Maftei, G.A.; Maglaviceanu, C.F. Biochemical Assesment of SalivaryParameters in Young Patients with Dental Lesions. Rev. Chim. 2019, 70, 4095–4097. [Google Scholar] [CrossRef]
  37. Jeong, Y.; Kim, J.W.; You, H.J.; Park, S.J.; Lee, J.; Ju, J.H.; Park, M.S.; Jin, H.; Cho, M.L.; Kwon, B.; et al. Gut microbial composition and function are altered in patients with earlyRheumatoid Arthritis. J. Clin. Med. 2019, 8, 693. [Google Scholar] [CrossRef] [Green Version]
  38. Sun, Y.; Chen, Q.; Lin, P.; Xu, R.; He, D.; Ji, W.; Bian, Y.; Shen, Y.; Li, Q.; Liu, C.; et al. Characteristics of Gut Microbiota in Patients With Rheumatoid Arthritis in Shanghai, China. Front. Cell. Infect. Microbiol. 2019, 9, 369. [Google Scholar] [CrossRef] [Green Version]
  39. Scher, J.U.; Sczesnak, A.; Longman, R.S.; Segata, N.; Ubeda, C.; Bielski, B.; Rostron, T.; Cerundolo, V.; Pamer, E.G.; Abramson, S.B.; et al. Expansion of intestinal Prevotellacopri correlates with enhanced susceptibility to arthritis. eLife 2013, 2, e01202. [Google Scholar] [CrossRef]
  40. Alpizar-Rodriguez, D.; Lesker, T.R.; Gronow, A.; Gilbert, B.; Raemy, E.; Lamacchia, C.; Gabay, C.; Finckh, A.; Strowig, T. Prevotellacopri in individuals at risk for rheumatoid arthritis. Ann. Rheum. Dis. 2019, 78, 590–593. [Google Scholar] [CrossRef]
  41. Moreno, J. Prevotellacopri and the microbial pathogenesis of rheumatoid arthritis. Reumatol. Clin. 2015, 11, 61–63. [Google Scholar] [CrossRef] [PubMed]
  42. Volkmann, E.R.; Hoffmann-Vold, A.M. Gastrointestinal tract microbiota modifications in systemic sclerosis. Eur. J. Rheumatol. 2020, 7 (Suppl. 3), S228–S236. [Google Scholar] [CrossRef]
  43. Yang, Y.; Zheng, W.; Cai, Q.Y.; Shrubsole, M.J.; Pei, Z.; Brucker, R.; Steinwandel, M.D.; Bordenstein, S.R.; Li, Z.; Blot, W.J.; et al. Cigarette smoking and oral microbiota in low-income and African-American populations. J. Epidemiol. Commun. Health 2019, 73, 1108–1115. [Google Scholar] [CrossRef]
  44. Picchianti-Diamanti, A.; Panebianco, C.; Salemi, S.; Sorgi, M.L.; Di Rosa, R.; Tropea, A.; Sgrulletti, M.; Salerno, G.; Terracciano, F.; D’Amelio, R.; et al. Analysis of gut microbiota in Rheumatoid Arthritis patients: Disease-related dysbiosis and modifications induced by Etanercept. Int. J. Mol. Sci. 2018, 19, 2938. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Dissick, A.; Redman, R.S.; Jones, M.; Rangan, B.V.; Reimold, A.; Griffiths, G.R.; Mikuls, T.R.; Amdur, R.L.; Richards, J.S.; Kerr, G.S. Association of periodontitis with Rheumatoid Arthritis: A pilot study. J. Periodontol. 2010, 81, 223–230. [Google Scholar] [CrossRef] [PubMed]
  46. Pischon, N.; Pischon, T.; Kröger, J.; Gülmez, E.; Kleber, B.M.; Bernimoulin, J.P.; Landau, H.; Brinkmann, P.G.; Schlattmann, P.; Zernicke, J.; et al. Association among rheumatoid arthritis, oral hygiene, andperiodontitis. J. Periodontol. 2008, 79, 979–986. [Google Scholar] [CrossRef] [PubMed]
  47. Abou-Raya, A.; Abou-Raya, S.; Abu-Elkheir, H. Periodontal disease and rheumatoid arthritis: Is there a link? Scand. J. Rheumatol. 2005, 34, 408–410. [Google Scholar] [CrossRef]
  48. Bingham, C.O., III; Giles, J.T.; Jones, P.E.; Bathon, J.M.; Bartlett, S.J. High prevalence of moderate to severe periodontal disease in rheumatoid arthritis patients. Arthritis Rheum. 2007, 56, S420. [Google Scholar]
  49. Eriksson, K.; Guozhong, F.; Lundmark, A.; Benchimol, D.; Lee, L.; Hu, Y.O.O.; Kats, A.; Saevarsdottir, S.; Anca, I.C.; Klinge, B.; et al. Periodontal health and oral microbiota in patients with Rheumatoid Arthritis. J. Clin. Med. 2019, 8, 630. [Google Scholar] [CrossRef] [Green Version]
  50. Scher, J.U.; Ubeda, C.; Equinda, M.; Khanin, R.; Buischi, Y.; Viale, A.; Lipuma, L.; Attur, M.; Pillinger, M.H.; Weissmann, G.; et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012, 64, 3083–3094. [Google Scholar] [CrossRef] [Green Version]
  51. Cheng, Z.; Do, T.; Mankia, K.; Meade, J.; Hunt, L.; Clerehugh, V.; Speirs, A.; Tugnait, A.; Emery, P.; Devine, D. Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis. Ann. Rheum. Dis. 2021, 80, 162–168. [Google Scholar] [CrossRef]
  52. Volkmann, E.R. Intestinalmicrobiome in scleroderma: Recent progress. Curr. Opin. Rheumatol. 2017, 29, 553–560. [Google Scholar]
  53. Dal Bello, F.; Hertel, C. Oral cavity as natural reservoir for intestinal lactobacilli. Syst. Appl. Microbiol. 2006, 29, 69–76. [Google Scholar] [CrossRef]
  54. Badet, C.; Thebaud, N.B. Ecology of lactobacilli in the oral cavity: A review of literature. Open Microbiol. J. 2008, 2, 38–48. [Google Scholar]
  55. Turroni, F.; Ventura, M.; Buttó, L.F.; Duranti, S.; O’Toole, P.W.; Motherway, M.O.; van Sinderen, D. Molecular dialogue between the human gut microbiota and the host: A Lactobacillus and Bifidobacterium perspective. Cell. Mol. Life Sci. 2014, 71, 183–203. [Google Scholar] [CrossRef]
  56. Rodríguez Mínguez, E.; Arqués, J.L.; Rodríguez, R.; Peirotén, A.; Landete, J.M.; Medina, M. Antimicrobial properties of probiotic strains isolated from breastfed infants. J. Funct. Foods 2012, 4, 542–551. [Google Scholar]
  57. Maldonado Galdeano, C.; Perdigón, G. The Probiotic Bacterium Lactobacillus casei Induces Activation of the Gut Mucosal Immune System through Innate Immunity. Clin. Vaccine Immunol. 2006, 13, 219–226. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Kishikawa, T.; Maeda, Y.; Nii, T.; Motooka, D.; Matsumoto, Y.; Matsushita, M.; Matsuoka, H.; Yoshimura, M.; Kawada, S.; Teshigawara, S.; et al. Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann. Rheum. Dis. 2020, 79, 103–111. [Google Scholar] [CrossRef]
  59. Johnson, M.E.; Franks, J.M.; Cai, G.; Mehta, B.K.; Wood, T.A.; Archambault, K.; Pioli, P.A.; Simms, R.W.; Orzechowski, N.; Arron, S.; et al. Microbiome dysbiosis is associated with disease duration and increased inflammatory gene expression in systemic sclerosis skin. Arthritis Res. Ther. 2019, 21, 49. [Google Scholar] [CrossRef] [Green Version]
  60. Reuter, G. The Lactobacillus and Bifidobacterium microflora of the human intestine: Composition and succession. Curr. Issues Intest. Microbiol. 2001, 2, 43–53. [Google Scholar]
  61. Ragab, G.; Atkinson, T.P.; Stoll, M. The Microbiome in Rheumatic Diseases and Infection; Springer International Publishing: New York, NY, USA, 2018. [Google Scholar] [CrossRef]
  62. Showalter, K.; Hoffmann, A.; DeCredico, N.; Thakrar, A.; Arroyo, E.; Goldberg, I.; Hinchcliff, M. Complementary therapies for patients with systemic sclerosis. J. Scleroderma Relat. Disord. 2019, 4, 187–199. [Google Scholar] [CrossRef]
  63. Aas, J.A.; Paster, B.J.; Stokes, L.N.; Olsen, I.; Dewhirst, F.E. Defining the normal bacterial flora of the oral cavity. J. Clin. Microbiol. 2005, 43, 5721–5732. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Shreiner, A.B.; Murray, C.; Denton, C.; Khanna, D. Gastrointestinal manifestations of systemic sclerosis. J. Scleroderma Relat. Disord. 2016, 1, 247–256. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Hoffmann, A.-M.; Volkmann, E.R. Gastrointestinal involvement in sistemic sclerosis. Effects on morbidity and mortality and new therapeutic approaches. J. Scleroderma Relat. Disord. 2019, 4, 33–39. [Google Scholar]
  66. Carlson, R.V.; Boyd, K.M.; Webb, D.J. The revision of the Declarationof Helsinki: Past, present and future. Br. J. Clin. Pharmacol. 2004, 57, 695–713. [Google Scholar] [CrossRef]
Microorganisms 09 01298 g001 550
Figure 1. Lactobacillus spp. rpoB sequences (expressed as ng−1 of target DNA) quantified by qPCR in gums and tongues of SSc patients and healthy subjects (control).
Figure 1. Lactobacillus spp. rpoB sequences (expressed as ng−1 of target DNA) quantified by qPCR in gums and tongues of SSc patients and healthy subjects (control).
Microorganisms 09 01298 g001
Table
Table 1. Controversial role of Lactobacillus spp. in systemic immune-mediated inflammatory diseases.
Table 1. Controversial role of Lactobacillus spp. in systemic immune-mediated inflammatory diseases.
SpeciesQuantity/FunctionReference
Lactobacillus caseiPrevention of diabetes mellitus in NOD mice[20]
Lactobacillus delbrueckii subsp. bulgaricusPrevention of collagen-induced arthritis in mice[21]
Lactobacillus GGOral intake improves arthritis in Lewis rats[22]
Lactobacillus caseiPotentiated induction of oral tolerance in EAA[23]
Lactobacillus paracasei/Lactobacillus plantarumImprovement of EAE, by Treg Microorganisms 09 01298 i001 and Th1/Th17 Microorganisms 09 01298 i002[24,25]
Lactobacillus spp. Microorganisms 09 01298 i003 in the gut of lupus-prone mice. Restoring normal number reverse SLE[26]
Lactobacillus spp.Increase in saliva of primary Sjögren’ssyndrome patients[28]
Lactobacillus spp./Lactobacillus salivarius Microorganisms 09 01298 i004 in RA patients’ gut, possible link with disease onset/progression[29,30]
NOD = non-obese diabetic; EAA = experimental autoimmune arthritis; EAE = experimental autoimmune encephalomyelitis; Treg = T regulatory cells; Th1/Th17 = T helper 1/T helper 17 cells; SLE = systemic lupus erythematosus; RA = rheumatoid arthritis.
Table
Table 2. Demographic, lifestyle and clinical characteristics of study patients.
Table 2. Demographic, lifestyle and clinical characteristics of study patients.
CharacteristicSScPatients (n = 29)Healthy Subjects (n = 23)
Age (years)
Mean ± SD
Range		 62 ± 12.43
43–80		 57.6 ± 8.47NS
44–72
Female gender2923
Smoking
current
former
never		 7
9
13		 7NS
5NS
11NS
LcSSc13NA
Disease duration (years)12NA
ANA positivity13 (100%)NA
ACA positivity13 (100%)NA
DcSSc15NA
Disease duration (years)14NA
ANApositivity15 (100%)NA
Anti-scl70 positivity15 (100%)NA
Overlapsyndrome1NA
Disease duration (years)22NA
ANA, anti-scl70, SSA, SSBPositive for allNA
cDMARDs16 (58.6%)NA
I.v.prostanoid13 (44.8%)NA
LcSSc = limited cutaneous systemic sclerosis; DcSSc = diffuse cutaneous systemic sclerosis; ANA = anti-nuclear antibodies; ACA = anti-centromere antibodies; cDMARDs = chemical Disease Modifying Anti-Rheumatic Drugs; NS = not significant; NA = not applicable.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Melchiorre, D.; Ceccherini, M.T.; Romano, E.; Cometi, L.; El-Aoufy, K.; Bellando-Randone, S.; Roccotelli, A.; Bruni, C.; Moggi-Pignone, A.; Carboni, D.; et al. Oral Lactobacillus Species in Systemic Sclerosis. Microorganisms 2021, 9, 1298. https://doi.org/10.3390/microorganisms9061298

AMA Style

Melchiorre D, Ceccherini MT, Romano E, Cometi L, El-Aoufy K, Bellando-Randone S, Roccotelli A, Bruni C, Moggi-Pignone A, Carboni D, et al. Oral Lactobacillus Species in Systemic Sclerosis. Microorganisms. 2021; 9(6):1298. https://doi.org/10.3390/microorganisms9061298

Chicago/Turabian Style

Melchiorre, Daniela, Maria Teresa Ceccherini, Eloisa Romano, Laura Cometi, Khadija El-Aoufy, Silvia Bellando-Randone, Angela Roccotelli, Cosimo Bruni, Alberto Moggi-Pignone, Davide Carboni, and et al. 2021. "Oral Lactobacillus Species in Systemic Sclerosis" Microorganisms 9, no. 6: 1298. https://doi.org/10.3390/microorganisms9061298

APA Style

Melchiorre, D., Ceccherini, M. T., Romano, E., Cometi, L., El-Aoufy, K., Bellando-Randone, S., Roccotelli, A., Bruni, C., Moggi-Pignone, A., Carboni, D., Guiducci, S., Lepri, G., Tofani, L., Pietramellara, G., & Matucci-Cerinic, M. (2021). Oral Lactobacillus Species in Systemic Sclerosis. Microorganisms, 9(6), 1298. https://doi.org/10.3390/microorganisms9061298

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop